Panayotis K Vlachakis,Maria Drakopoulou,Panagiotis Theofilis et al.
Panayotis K Vlachakis et al.
Patients with Fontan circulation represent a pharmacologically distinct population in whom the haemodynamic consequences of single-ventricle physiology alter every phase of drug disposition in ways that current prescribing practice systemat...
Panayotis K Vlachakis,Maria Drakopoulou,Panagiotis Theofilis et al.
Panayotis K Vlachakis et al.
Patients with Fontan circulation represent a pharmacologically distinct population in whom the haemodynamic consequences of single-ventricle physiology alter every phase of drug disposition in ways that current prescribing practice systemat...
May the Universal Truth rest in peace and us with Her? On how to understand inconsistency in and among pharmacological trials [0.03%]
谨将此文献给宇宙真理。如何理解药理学试验中的不一致性？
Maura Marcucci,Holger J Schünemann,Federico Germini
Maura Marcucci
Authors' reply to: "Stent-Free Is Not Risk-Free: Risk-Defined DAPT After DCB-Only PCI in ACS" [0.03%]
对《无支架不等于无风险：急性冠脉综合征患者行只用药物涂层球囊成形术后的基于风险的DAPT》的意见答复
Anton Håkansson,Sacharias von Koch,Axel Dahlgren et al.
Anton Håkansson et al.
Beyond API-CAT: The remaining challenges of extended anticoagulation for cancer-associated thrombosis [0.03%]
超越API-CAT：癌症相关血栓延长抗凝的剩余挑战
Marcello Di Nisio,Tzu-Fei Wang
Marcello Di Nisio
Reply to Zhang and Lou: beta-blockers after myocardial infarction should be guided by indication, ejection fraction, and contemporary evidence [0.03%]
关于张文和娄文的来信：急性心肌梗死后β blocker的使用应基于适应症、射血分数以及当前证据指导建议回复
Borja Ibanez,Xavier Rossello
Borja Ibanez
Bleeding risk assessment in patients with new-onset atrial fibrillation after CABG [0.03%]
冠脉搭桥术后新发房颤患者的出血风险评估
Anders Jeppsson,Mary Rezk,Florian E M Herrmann
Anders Jeppsson